Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation.
Vasodilatory hypotension requiring the administration of catecholamine pressors may occur following cardiopulmonary bypass. We investigated the hemodynamic response to arginine vasopressin (AVP) in 20 patients who developed vasodilatory hypotension after cardiac transplantation. In this cohort, AVP infusion (0.1 U/min) significantly increased mean arterial pressure and decreased norepinephrine requirements, allowing rapid discontinuation of norepinephrine infusions in 7 patients. Judicious use of this novel agent in appropriately selected patients may minimize end-organ sequelae of hypotension and high-dose catecholamine therapy.
Argenziano
M
M
Department of Surgery, Columbia University College of Physicians, New York, NY, USA.
Chen
J M
JM
Cullinane
S
S
Choudhri
A F
AF
Rose
E A
EA
Smith
C R
CR
Edwards
N M
NM
Landry
D W
DW
Oz
M C
MC
D001127:Arginine Vasopressin / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D005260:Female; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D007022:Hypotension / Q000188:drug therapy* / Q000209:etiology; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014664:Vasodilation / Q000187:drug effects*
D014662:Vasoconstrictor Agents; D001127:Arginine Vasopressin